257 related articles for article (PubMed ID: 22854646)
1. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
2. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
4. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
5. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
Clardy CW; Forristal J; Strife CF; West CD
Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
[TBL] [Abstract][Full Text] [Related]
6. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
7. A C3 convertase assay for nephritic factor functional activity.
Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
[TBL] [Abstract][Full Text] [Related]
8. Causes of alternative pathway dysregulation in dense deposit disease.
Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
[TBL] [Abstract][Full Text] [Related]
9. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
10. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
11. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
12. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
13. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
14. Activation of the alternative complement pathway.
Fearon DT
CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
[No Abstract] [Full Text] [Related]
15. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
16. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH
Front Immunol; 2022; 13():1073802. PubMed ID: 36846022
[TBL] [Abstract][Full Text] [Related]
17. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
18. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.
Blom AM; Corvillo F; Magda M; Stasiłojć G; Nozal P; Pérez-Valdivia MÁ; Cabello-Chaves V; Rodríguez de Córdoba S; López-Trascasa M; Okrój M
J Clin Immunol; 2016 Jul; 36(5):517-27. PubMed ID: 27146825
[TBL] [Abstract][Full Text] [Related]
19. C3 nephritic factor stabilization of the classic C3 convertase: a role for C2 in C3 nephritic factor activity.
McLean RH; Nilson SH
Proc Soc Exp Biol Med; 1979 Jul; 161(3):358-63. PubMed ID: 461464
[No Abstract] [Full Text] [Related]
20. A Monoclonal Antibody That Provides a Model for C3 Nephritic Factors.
Hourcade DE; Mitchell LM
Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):9-14. PubMed ID: 36853837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
